IMAX enters September with an unusual split: shorts are quietly covering, analysts are lifting targets, yet the stock fell 5% on the week to $51.13 — and options traders are the most defensively positioned they have been in months.
The options story is the clearest signal of near-term caution. The put/call ratio has roughly doubled since late July, climbing from around 1.6 to 4.03 — well above its 20-day average of 3.07 and near the most defensive reading outside of the 52-week spike at 9.13. The z-score of 1.19 is elevated but not extreme, suggesting this is a gradual shift in hedging behaviour rather than a panic trade. What makes the timing notable is that it coincides with a week where the stock gave back 5% despite the broader analyst community marking up targets.
The short side tells a less alarming story. Short interest has eased meaningfully — down 4% on the week and roughly 700,000 shares below the mid-August peak — and now registers 12.5% of the free float, off a recent high closer to 14%. Borrow conditions remain easy: availability is 327%, meaning there are roughly three shares available to borrow for every one already borrowed, and the cost to borrow holds near 0.5%. The ORTEX short score has also drifted lower, from 69 at the August 20 peak to 63.4, reflecting that pressure in the lending market is easing. Positioning looks cautious rather than crowded: the shorts who were most aggressive in August have been trimming, not adding.
The Street, meanwhile, has turned noticeably more constructive. Macquarie raised its target to $55 this week while maintaining Outperform. B. Riley lifted to $61 — the highest on record in this cycle — with a Buy. The bull case centres on a diversified content slate, a proven brand premium, and a forward EPS momentum score in the 85th percentile of the universe, with 12-month forward estimates running well above year-ago levels. The mean Street target of $53.56 sits modestly above the current price, implying limited upside from consensus alone. Bears point to Hollywood concentration risk, China regulatory exposure, and a box office model that remains hostage to a handful of blockbuster releases each quarter. The EV/EBITDA multiple of 14.7x has been easing — down half a point over 30 days — suggesting some valuation relief but not a dramatic re-rating.
The ownership picture adds another layer of interest. Kevin Douglas holds a Schedule 13D activist position — the highest-conviction filing type under SEC rules — disclosing 15.5% of the class as of March, down from 16.5% previously. That he has trimmed slightly but remains the largest declared holder with an activist mandate is worth tracking. Institutional flows elsewhere show broad accumulation: BlackRock, Goldman Sachs, Columbia, Driehaus, and Congress Asset Management all added shares in the most recent reported period. The insider picture is more mixed. The CFO sold $1.1 million in open-market shares on August 24, and the President of IMAX Global Theatres sold $1.6 million the following day — both discretionary, neither under a 10b5-1 plan. The net insider position over 90 days is -58,000 shares worth roughly $3.2 million. Insider sales at these levels, while not catastrophic, add a note of caution to the bullish analyst tone.
The next earnings event is scheduled for October 23. The last print on July 23 delivered a 10% single-day gain and an 21% five-day move — the stock's strongest post-earnings reaction in recent memory. The prior event, in late July, added another 2.6% the next day. That history means the October print carries significant weight, and the widening put/call ratio may partly reflect investors beginning to position around that outcome. What to watch between now and then: whether the short score stabilises around 63 or resumes its August climb, whether the activist position from Kevin Douglas generates any further filings, and whether the gap between analyst targets and the current price begins to close — or widens further as the options market's defensive lean suggests it might.
See the live data behind this article on ORTEX.
Open IMAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
